<DOC>
	<DOCNO>NCT02564367</DOCNO>
	<brief_summary>Multicenter trial Germany : Feasibility Study Adjuvant Treatment S-1 Patients R0-Resection Adenocarcinoma Stomach Esophagogastric Junction aim show feasibility tolerability two different adjuvant S-1 treatment regimen Caucasian patient determine recommend dose treatment regimen .</brief_summary>
	<brief_title>Feasibility Study Adjuvant Treatment With S-1 Patients After R0-Resection Adenocarcinoma Stomach Esophagogastric Junction</brief_title>
	<detailed_description>Patients enrol two cohort . The cohort 1 d2 conduct consecutively , start cohort 1 . Cohort 1 consists 30 patient receive S-1 twice daily 18 cycle ( D1-14 q 3 wks ) . Cohort 2 consist 30 patient receive S-1 twice daily 9 cycle ( D1-28 , q 6 wks ) . Both cohort start 2x 30 mg/m^2 BSA . Two dose reduction allow per protocol .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>1 . Patient sign date informed consent start specific protocol procedure 2 . Adult Caucasian patient ≥ 18 year age 3 . Histologically confirm diagnosis adenocarcinoma stomach esophagogastric ( EG ) junction classify uT2/uT3/uT4 , N category , M0 uT , N+ , M0 patient ( patient receive neoadjuvant chemotherapy ) pT2/pT3/pT4 , N category , M0 pT , N+ , M0 ( patient receive primary surgery ) accord Union international contre le cancer ( UICC ) TNM edition 7 . 4 . R0resection neoadjuvant treatment . However , patient also include neoadjuvant treatment could perform due medical indication primary surgery ( perforation , bleed etc . ) perform due understaging . 5 . D2 lymph node dissection perform 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 7 . Consent translational research perform tumor tissue primary tumor remove resection surgery . Translational research perform upon completion routine histological pathological evaluation tumor 8 . Females childbearing potential ( FCBP ) must negative pregnancy test within 7 day first application study treatment must agree use effective contraceptive birth control measure ( Pearl Index &lt; 1 ) course trial least 6 month last application S1 . Females childbearing potential ( FCBPs ) include confirmed menstrual period ( applicable , i.e . still menses ) must negative highly sensitive pregnancy test within 7 day prior first application study treatment must agree use highly effective contraceptive birth control measure ( Pearl Index &lt; 1 ) course trial least 6 month last application S1 . Such highly effective birth control method include : oral , intravaginal , transdermal combine hormonal contraception associate inhibition ovulation oral , injectable , implantable progesteroneonly hormonal contraception associate inhibition ovulation intrauterine device intrauterine hormonereleasing system bilateral tubal occlusion commitment complete abstinence heterosexual contact A female subject follow menarche consider childbearing potential unless naturally amenorrhoeic ≥ 1 year without alternative medical reason , unless permanently sterile ( permanent sterilisation method include hysterectomy , bilateral salpingectomy bilateral oophorectomy ) . 9 . Males must agree father child course trial least 6 month last administration S1 must agree use condom course trial least 6 month last administration S1 case sexual intercourse FCBP pregnant female . 10 . Patient must able take medication orally within eight week surgery start S1 . 11 . Normal cardiac function demonstrate Electrocardiogram ( ECG ) echocardiogram ( LVEF ≥ 55 % ) 12 . Adequate bone marrow , hepatic renal function define Absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L Haemoglobin ≥ 9 g/dL Platelets ≥ 100 x 10^9/L Albumin ≥ 2.5 g/dL Total bilirubin ≤ 2 mg/dL GOT/AST GPT/ALT ≤ 3 x Upper normal limit ( ULN ) Calculated creatinine clearance accord MDRD equation ≥ 50 mL/min 13 . Patient 's legal capacity consent study participation 1 . Metastatic disease ( exclusion metastatic disease postoperative CT MRI scan thorax abdomen within 3 week prior start adjuvant therapy ) 2 . Polyneuropathy &gt; grade 1 ( NCI CTCAE version 4.0 ) 3 . Evidence ascites liver cirrhosis 4 . Patient pregnant breastfeeding 5 . Patient underwent major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment , anticipate need major surgical procedure course study . 6 . Heart failure ≥ NYHA functional classification system grade 2 7 . Myocardial infarction , unstable angina , cardiac angioplasty stenting procedure within last 6 month . 8 . Medical history pulmonary fibrosis interstitial lung disease ( ILD ) 9 . Active uncontrolled bacterial , viral , fungal infection require systemic treatment 10 . Known HIV , HBV , HCVinfection 11 . Concurrent disease condition would make patient inappropriate study participation would interfere patient 's safety . 12 . Psychological , familial , sociological , geographical condition permit compliance protocol . 13 . Any cancer therapy ( chemotherapy , radiation therapy , biologic therapy , immunotherapy , hormonal therapy ) resection surgery requirement concurrent cancer treatment study treatment S1 . 14 . Participation another clinical trial treatment investigational drug surgery study treatment S1 . 15 . Known immediate delay hypersensitivity active substance S1 ( tegafur , gimeracil , oteracil ) excipients drug chemically relate S1 ( e.g . 5fluorouracil ) 16 . History severe unexpected reaction fluoropyrimidine therapy 17 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 18 . Treatment DPD inhibitor , include sorivudine chemically related analogue brivudine within 4 week start study drug study treatment 19 . Previous concurrent malignant tumor disease underlie tumor disease exception cervical cancer situ , adequately treat basal cell carcinoma squamous cell carcinoma skin , superficial bladder tumor ( Ta , Tis , T1 ) curatively treat tumor &gt; 5 year prior enrolment 20 . Known alcohol abuse drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>